Meeting
2022 ASCO Annual Meeting
Defining resistance mechanisms to CDK4/6 inhibition in hormone receptor-positive HER2-negative metastatic breast cancer (MBC) through a machine learning approach applied to circulating tumor DNA (ctDNA).
Authors
Lorenzo Gerratana
Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy
Lorenzo Gerratana , Carolina Reduzzi , Andrew A. Davis , Marko Velimirovic , Katherine Clifton , Whitney L Hensing , Ami N. Shah , Charles Sichao Dai , Paolo D’Amico , Jeannine Donahue , Qiang Zhang , Alexandro Membrino , Firas Hazem Wehbe , Arielle Janine Medford , William John Gradishar , Amir Behdad , Cynthia X. Ma , Seth Andrew Wander , Fabio Puglisi , Massimo Cristofanilli
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3055)
DOI
10.1200/JCO.2022.40.16_suppl.3055
Abstract #
3055
Poster Bd #
47
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Genomic alterations in appendiceal carcinoma using circulating DNA.
First Author: Walid Labib Shaib
Poster
2022 ASCO Annual Meeting
Molecular alterations associated with rapid progression following CDK4/6 inhibitors (CDKi) in metastatic hormone receptor–positive breast cancer (mHRBC).
First Author: Malinda T West
Poster
2020 ASCO Virtual Scientific Program
Acquired genomic alterations in circulating tumor DNA from patients receiving abemaciclib alone or in combination with endocrine therapy.
First Author: Matthew P. Goetz
Poster
2019 ASCO Annual Meeting
Next-generation sequencing (NGS) results among hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) patients treated with a CDK4 & 6 inhibitor: A retrospective observational study based on real‑world data.
First Author: Erika Paige Hamilton